Compare ADMA Biologics Inc (ADMA) vs Toronto-Dominion Bank (TD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADMA Biologics Inc vs Toronto-Dominion Bank — how do they compare? ADMA Biologics Inc trades at $9.88 (market cap $2.22B), while Toronto-Dominion Bank trades at $121.35 (market cap $200.48B). The key difference: Toronto-Dominion Bank is far larger — about 90.3× ADMA Biologics Inc's market cap, and Toronto-Dominion Bank pays a 2.63% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | TD | |
|---|---|---|
Market Cap | $2.22B | $200.48B |
Sector | Health | Financials |
52-Week High | $20.38 | $124.80 |
52-Week Low | $7.60 | $72.85 |
Enterprise Value | $2.29B | — |
Dividend Yield | — | 2.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.83, up 0.82% today, with strong profitability metrics including a 32.98% net income margin and 41.9% ROE. Recent earnings show mixed results, with a beat in Q4 2025 but misses in Q1 and Q2 2026. Technical indicators are bullish overall, though RSI levels suggest overbought conditions. The stock faces significant legal headwinds from multiple securities fraud class actions filed in August 2026.
The outlook is cautiously optimistic given solid fundamentals and analyst support, but legal risks and recent earnings misses pose near-term challenges. Upside potential exists if the company can maintain profitability and resolve litigation, while downside risks include prolonged legal proceedings and execution missteps.
TD trades at $123.38, up 1.9% today, with a bullish technical signal from moving averages. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS expected at $1.70. Revenue grew to $61.28 billion in 2025, and the net income margin improved to 33.51%. A dividend of $1.12 is scheduled for payment on July 31, 2026.
The outlook is positive, supported by strong earnings momentum and a unanimous analyst buy/hold consensus with no sell ratings. Key risks include volatile cash flows from operations and high leverage, with total liabilities of $1.95 trillion. The stock offers value with a P/E of 19.88 and robust profitability metrics like ROE of 12.59%.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Toronto-Dominion Bank
Toronto-Dominion is one of Canada's two largest banks and operates three business segments: Canadian retail banking, U.S. retail banking, and wholesale banking. The bank's U.S. operations span from Maine to Florida, with a strong presence in the Northeast. It also has a 13% ownership stake in Charles Schwab.
Read more on TD →
